Numerous studies have demonstrated a relationship between the extracellular matrix protein BIGH3 and variations in the malignant properties of different cancer cell types, including osteosarcoma cells. BIGH3 protein can suppress and promote tumor growth, even on the same cancer cell type, indicating that contextual cues regulate BIGH3-mediated divergent outcomes. We employed a multicellular tumor spheroid model to study the effects of BIGH3 with respect to physical and molecular features of three-dimensional tumor growth. The results demonstrated that exogenous recombinant BIGH3 blocked the development of multicellular large tumor spheroids so that only small spheroids formed. The effect was dependent on the BIGH3 concentration in the growth medium and the time of incubation of BIGH3 with the osteosarcoma cells in the spheroid model. TGF-β1 signaling induced multicellular tumor spheroids to synthesize a greater quantity of BIGH3 relative to non-treated spheroids. The TGF-β1-mediated increase in BIGH3 protein antagonized the development of multicellular large spheroids. Anti-BIGH3 antibody, and an inhibitor of TGF-β1 signaling, blocked the antagonistic effect induced through TGF-β1 stimulation and BIGH3 protein expression, resulting in the formation of multicellular large spheroids. Immunohistochemistry detected BIGH3 at cell bodies within the spheroid stroma, suggesting osteosarcoma cell-surface proteins bind BIGH3. Flow cytometry demonstrates that osteosarcoma cells interact with soluble BIGH3, and solid-phase cell adhesion assays show that osteosarcoma adhesion to BIGH3 substratum is mediated by integrin α4β1. However, anti-α4 antibody did not attenuate the BIGH3-mediated antagonism toward formation of multicellular large spheroids. We conclude that TGFβ1 and BIGH3 suppress the development of large osteosarcoma tumors.
Introduction
As an in vitro model of tumor progression, propagation of Multicellular Tumor Spheroids (MTS) provides a convenient means to study the effects of the extracellular matrix (ECM) on tumor formation. Various tumor cell types have been propagated as MTS comprising cells and their ECM, and exhibiting behavior similar to that of tumors in vivo [1] . It is well established that cells on two-dimensional substrates of various polyresin plastics provide valuable information regarding ECM synthesis, cell signaling, intermediate stroma, and in a centralcore, which can become a necrotic environment [5] . Molecules of the ECM can play significant roles in tumor progression, mechanically stabilizing and affecting tumor morphology and tumor cell viability and metastasis [1] [6] [7] . The human gene called TGFBI encodes for the ECM protein BIGH3, which was discovered investigating the effects of the cytokine TGFβ1 on adenocarcinoma tumor progression [8] . The BIGH3 gene was cloned and sequenced in 1992 [8] , and subsequently BIGH3 was proposed to function as a tumor suppressor protein [9] . TGFBI −/− mice exhibited predisposition to develop various tumors, underscoring BIGH3's tumor suppressing property. Isolated TGFBI −/− mouse embryonic fibroblasts showed chromosomal abnormalities, increased cyclin D1 synthesis, and cell proliferation [10] .
BIGH3 suppressed proliferation of osteosarcoma [11] , lung [12] [13] [14] [15], ovarian [16] [17] [18] , breast [19] , prostate cancer cells [12] , and exhibited anti-angi-ogenic and anti-tumorigenic activities [20] . In contrast, other studies show that BIGH3 protein stimulates cancer cell aggressiveness, including osteosarcoma metastasis [21] , colon cancer [22] , oral squamous carcinoma [23] [24] , and astrocytoma progression [25] . Integrins, apoptosis [11] , chromosomal abnormalities [26] , and cell motility and chemoresistance to lung and ovarian cancer cells [27] have been implicated in molecular mechanisms that underlie BIGH3's divergent effects on tumors progression. Central to BIGH3 biology is a strong response of the BIGH3 gene to TGF-β1 stimulation [9] , and the regulatory action in play between TGF-β1 and integrins [28] [29] . Thus, TGF-β1 staining is a contextual cue for transcription, translation and secretion of BIGH3. Despite the accumulating evidence of differential roles that BIGH3 mediates in different cancer and cancer cell types, there has been a paucity of information on the effect of BIGH3 protein on cancer cell behavior in the context of a three-dimensional tumor environment. We previously reported BIGH3 mediates apoptosis in MG-63 osteosarcoma cell monolayers [11] . To this end we sought to examine the effect of BIGH3 on developing osteosarcoma tumor spheroids by using a simple yet well-recognized MTS model system as a convenient method to examine tumor response to ECM protein. 
Purification of BIGH3
The serum-free conditioned medium taken from CHO cells expressing human BIGH3
was applied over heparin, hydroxyapatite and anion exchange resin bed volumes of 10 ml, 2 ml, and 2 ml, respectively. Chromatography buffers were Buffer A; 50 mM Tris, 50 mM NaCl, pH 5.5. Buffer B; Buffer A containing 1 M NaCl. Buffer C; 10 mM NaPO 4 buffer, pH 6.8. Buffer D; 0.4 M NaPO 4 buffer, pH 6.8. Buffer E; 10 mM Tris, 10 mM NaCl, pH 5.5. Buffer F was comprised of Buffer E containing 1 M NaCl. Purity and concentration of BIGH3 was assessed using SDS PAGE and bicinchoninic acid protein quantification (Pierce) respectively. Further details are described in the results section.
Cell Culture
Growth media contained 50 µg/ml each of penicillin and streptomycin sulfate. Cells were maintained in a 37˚C incubator saturated with humidified 5% CO 2 
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MTS Fixation, Embedding and Immunohistochemical Staining
Day 3 osteosarcoma MTS were fixed in 4% paraformaldehyde and embedded in paraffin. A Microm HM325 microtome (Walldorf, Germany) cut 10-µm thick sections, which were then mounted onto charged microscope slides. Following deparaffinization and rehydration, sections were incubated in a solution of 0.005% trypsin-EDTA as described [38] and blocked with 10% normal goat serum. BIGH3 was detected by incubating sections at 4˚C overnight with anti-BIGH3 antibody followed by a second antibody conjugated to horseradish peroxidase. DAB served as the chromogen substrate to localize antibodies.
Flow Cytometry
Osteosarcoma cells were incubated for three hours with 10 µg/ml BIGH3 and then washed and mixed with anti-BIGH3 antibody, 1 mg/ml anti-integrin β1 antibody, or negative control antibody. Cells were then washed and incubated for 30 minutes with 1 mg/ml fluorescein-conjugated goat anti-rabbit or goat anti-mouse antibody. Nonspecific fluorescence was determined by a 30-minute incubation of osteosarcoma cells with 1 mg/ml fluorescein-conjugated second antibody only. Following washes, the cells were fixed with 4% paraformaldehyde in PBS (PBS in mM; 0. 
Cell Adhesion
Substratum for osteosarcoma cells were prepared by treating microtiter wells with 10 µg/ml human recombinant BIGH3. 8 µg/ml human fibronectin and 1% BSA in PBS. To reduce the possibility that endogenous protein synthesis may affect the outcome of adhesion experiments, DMEM containing 10 µg/ml cycloheximide was used to pre-incubate cells 1 hour before experiments. An identical concentration of cycloheximide was included in all subsequent adhesion assay solutions. Cells used in adhesion assays were released from monolayer culture using 1 mM EDTA in divalent cation-free PBS, washed, and suspended at a density of 5 × 
Statistical Analysis
Analysis of the cell adhesion results was assessed by analysis of variance (ANOVA) and MTS formation data by the Mann-Whitney U nonparametric test. Statistical significance was accepted when P< 0.05.
Results
Recombinant BIGH3 Purification. Serum-free medium conditioned by CHO cells expressing human BIGH3 was dialyzed against distilled water and lyophilized. The lyophilized material was rehydrated in Buffer A ( Integrin α4β1 Mediates Osteosarcoma Cell Adhesion onto a BIGH3 Substratum.
Solid-phase cell adhesion assays were used to test directly and immunologically for integrins involved in osteosarcoma cell interaction with BIGH3. When seeded onto a BIGH3 substratum approximately 75% of the added osteosarcoma cells attached and spread within 90 minutes at 37˚C (Figure 9 Untreated). MG-63 cells express the integrin subunits α2, α3, α4, α5, α6 and β1 [39] . To determine whether these integrin types mediate adhesion of osteosarcoma cells to BIGH3, a set of corresponding function-perturbing anti-integrin antibodies were tested. Preincubation of cells with anti-α4 antibody, and anti-β1 antibody, significantly reduced attachment of osteosarcoma cells by 92% and 93% respectively ( Figure 9 Anti-α4 and Anti-β1, P < 0.01). Other anti-integrin antibodies did not achieve statistical significance. These data indicate that α4β1 integrin mediates MG-63 cell adhesion onto a BIGH3 substratum. Extending this observation, we hypothesized that α4β1 integrin promotes osteosarcoma cell MTS for-
mation. This hypothesis was tested using the exact paradigm to generate MTS in the presence of α4 and β1 antibodies. Unexpectedly, anti-α4 and anti-β1 antibodies did not block the antagonistic effect of BIGH3 on MTS formation, indicating the BIGH3-me- Figure 9 . Anti-integrin α4 and β1 antibodies reduce cell adhesion onto a BIGH3 substratum.
Osteosarcoma cell attachment to a substratum comprised of 10 µg/ml BIGH3 (Untreated). Anti-α4 and Anti-β1 integrin subunit antibodies blocked cell attachment. The reduction in cell attachment is significant (P < 0.01, n = 5) when compared to untreated conditions. diated inhibition of large MTS formation is independent of α4β1, while revealing that α4β1 mediates osteosarcoma cell attachment to a BIGH3 substratum.
Discussion
The primary objective of this study was to document the influence of BIGH3 on osteosarcoma cell MTS development. MTS cell culture models are popular systems that support a vascular tumor growth [1] . We employed a liquid-aga-rose overlay paradigm that promoted the formation of MTS. Using TUNEL assays, we previously published findings that TGFβ1 significantly increased BIGH3 expression and apoptosis in monolayers of osteosarcoma MG-63 and Saos-2 cells [11] , retinal endothelial cells [44] , retinal pericytes [45] , and renal tubule epithelial cells [46] . Others have shown BIGH3-mediated apoptosis in CHO and lung adenocarcinoma cells [47] , HeLa and transformed corneal epithelial cells [48] . TGF-β1 strongly upregulates expression of BIGH3 protein, which binds different integrins including α1β1 [49] , α3β1 [50] [51], αvβ5 [52] , α6β4 [53] and α7β1 [54] , implicating integrins in BIGH3 biology in disease. Thus, TGFβ1, BIGH3, integrins and apoptosis were highlighted as playing potential roles in osteosarcoma tumor biology. The results of this study demonstrate BIGH3 markedly blocked the progression of osteosarcoma cells to large MTS. When BIGH3 was added to MG-63 cells in our tumor model, small MTS formed only, when compared to the large MTS that formed without BIGH3, but otherwise cultured under identical conditions. This outcome formed the basis for three hypotheses that were tested in subsequent experiments in this study. First, a natural expectation was that BIGH3-mediated apoptosis was involved in the failure of osteosarcoma cells to form large MTS. Second, TGFβ1 was expected to increase BIGH3 synthesis and apop-tosis. A third proposition was that integrins were involved in the mechanism underlying BIGH3's inhibition of tumor growth. TUNEL assays were used to quantify apoptosis in BIGH3-treated small MTS. The results did not conclusively demonstrate whether the impediment of large MTS formation was related to cell apoptosis. This MTS study strongly implicates BIGH3 protein as playing a causative role in the failure of osteosarcoma cells to form large MTS. Although TUNEL-positive cells were detected, the results did not achieve significance. MTS assays were typically carried out for seven days. Little, if any MTS phenotypic differences were evident for up to 2 days following initiation of the MTS cultures. By 3 days BIGH3-treated osteosarcoma cells formed small MTS comprised of a few to approximately 30 cells. Even at day 7 the small MTS phenotype consisted of approximately 1.0 -1.5 × 10 3 cells, which was comparatively small relative to non-treated cells that progressed to form a sheet-like mass culminating in large MTS. IHC comparisons of BIGH3 in treated and non-treated MTS indicate a homogenous distribution of BIGH3. Intense BIGH3 staining was evident in the internal stroma of non-treated MTS, and even greater intensity throughout the treated small MTS. The latter is likely explained by the BIGH3 that was added-back to the medium in order to treat the cells. The dense punctum staining observed in treated MTS that were stained with anti-fibronectin or anti-BIGH3 antibodies will require additional experiments to determine their relevance, if any. Osteosarcoma cell de novo synthesis of BIGH3 was not sufficient to antagonize the formation of large MTS. However, adding exogenous TGFβ1 increased BIGH3 expression in the MTS and resulted in the antagonistic effect on development of large MTS. Indeed, TGFβ1-treated MTS were indistinguishable from the MTS formed when BIGH3 protein was added to the culture medium. TGFβ1 stimulates various genes encoding for molecules of the ECM. BIGH3 binds ECM molecules including proteoglycans [55] , heparin (this study and [54] [56]), collagens [57] , and fibronectin [56] . Thus we cannot rule out the possibility that BIGH3 interacts with different ECM molecules to bring about antagonism of large MTS. Importantly, however, whether from osteosarcoma cell synthesis or from other cellular sources in the tumor environment, anti-BIGH3 antibody blocked the BIGH3-mediated antagonism, indicating that BIGH3 protein itself, was involved in the regulation of MTS size. Flow cytometry confirmed that osteosarcoma cells bind to soluble BIGH3 suggesting a high-affinity interaction. Osteosarcoma cell adhesion onto a 2-dimensional planar BIGH3 substratum was dependent on the concentration of BIGH3 in the substratum, and on the time of incubation, suggesting that cell interaction with BIGH3 is receptor mediated. A set of function-inhibiting anti-integrin antibodies was used to test whether integrins mediate osteosarcoma cell adhesion on BIGH3. Function-blocking anti-α4 and anti-β1 antibodies inhibited more than 90% of the number of osteosarcoma cells binding to a BIGH3 substratum, implicating integrin α4β1inosteosarcoma cell attachment onto a BIGH3 substratum. Integrin antibodies, including anti-α4 and -β1 did not affectBIGH3's antagonism toward large MTS development when added at culture initiation, or when a 30-minute pre-incubation of osteosarcoma cells with integrin antibodies was implemented in the assay paradigm.
Although the BIGH3 effect on MTS size is distinct, its physiological meaning is not yet apparent. One possibility that we examined is that BIGH3 functions as a tumor suppressor that diminishes tumor viability by induction of apoptosis. In support of this possibility TGFBI −/− mice are predisposed to form tumors when compared to wild type mice [10] . Other investigators have shown that BIGH3 is downregulated in tumors and tumor cells of mesenchyme origin, indicating a tumor suppressor role [9] [58] [59] [60] [61] [62] . We have shown that BIGH3 induces a significant increase in apoptosis in monolayers of osteosarcoma cells [11] , and other different cell types [11] MTS were ≥ 400 μm diameter [63] [64] [65] , however this has recently been questioned: In MG-63 osteosarcoma MTS that were ≤ 100 μm diameter, hypoxia-responsive element (HRE) activity was evident, while, interestingly, HRE activity was almost undetectable in MG-63 monolayers, indicating there is different transcriptional and translational activity in 3-dimensional MTS as opposed to cell monolayers [66] . Thus small MTS of osteosarcoma cells showing high HRE activity, as with hypoxia-inducible factor 1, would potentially give rise to exceedingly aggressive cancer cells.
In summary, BIGH3 protein has a marked influence on tumorigenesis in vitro. Mechanistically, at least part of the activity includes TGFB1, TGFB1 signaling, and BIGH3 protein. Potential therapeutic targets identified in this study include TGFβ1, molecules in the TGFβ1-receptor signaling pathway, and BIGH3 itself.
